Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer - Concepedia

Concepedia

Publication | Open Access

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

DOI Full Paper Access

162

Citations

25

References

2019

Year

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean‐Yves Scoazec,

Clinical Cancer Research

Abstract

This study shows that mechanisms of resistance to lorlatinib are diverse and complex, requiring new therapeutic strategies to tailor treatment upon disease progression.

References

	Year	Citations

Page 1